Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico-SMART 2017-2021.
| Autor: | Karlowsky JA; IHMA, 2122 Palmer Drive, Schaumburg, IL 60173, USA.; Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Room 543-745 Bannatyne Avenue, University of Manitoba, Winnipeg, MB R3E 0J9, Canada., Lob SH; IHMA, 2122 Palmer Drive, Schaumburg, IL 60173, USA., Siddiqui F; Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, USA., Polis T; MSD Brasil, Av. Chucri Zaidan, 296-Vila Cordeiro, São Paulo 04583-110, Brazil., Vallejo JL; MSD Mexico, Av. San Jerónimo 369, Tizapán San Ángel, Tizapán, Álvaro Obregón, 01090 Mexico City, Mexico., Young K; Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, USA., Motyl MR; Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, USA., Sahm DF; IHMA, 2122 Palmer Drive, Schaumburg, IL 60173, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | JAC-antimicrobial resistance [JAC Antimicrob Resist] 2024 May 24; Vol. 6 (3), pp. dlae077. Date of Electronic Publication: 2024 May 24 (Print Publication: 2024). |
| DOI: | 10.1093/jacamr/dlae077 |
| Abstrakt: | Objectives: To investigate the activities of ceftolozane/tazobactam and imipenem/relebactam against Escherichia coli , Klebsiella pneumoniae and Pseudomonas aeruginosa isolated from hospitalized patients in Mexico in 2017-2021. Methods: MICs were determined by CLSI broth microdilution and interpreted using CLSI M100 breakpoints. β-Lactamase genes were identified in ceftolozane/tazobactam-, imipenem/relebactam-, and/or imipenem-non-susceptible isolates. Results: Ceftolozane/tazobactam and imipenem/relebactam inhibited 89% and 99% of E. coli isolates ( n = 2337), and 87% and 94% of K. pneumoniae isolates ( n = 1127). Sixty-four percent of E. coli and 47% of K. pneumoniae had an ESBL non-carbapenem-resistant Enterobacterales (ESBL non-CRE) phenotype. Eighty-six percent and 91% of ESBL non-CRE E. coli and K. pneumoniae were ceftolozane/tazobactam susceptible, and 99.9% and 99.8% were imipenem/relebactam susceptible. Ceftolozane/tazobactam was the most active agent studied against P. aeruginosa ( n = 1068; 83% susceptible), 9-28 percentage points higher than carbapenems and comparator β-lactams excluding imipenem/relebactam (78% susceptible). Ceftolozane/tazobactam remained active against 35%-58%, and imipenem/relebactam against 32%-42%, of P. aeruginosa in meropenem-, piperacillin/tazobactam-, and cefepime-non-susceptible subsets. The majority of isolates of ceftolozane/tazobactam-non-susceptible E. coli carried an ESBL, whereas among ceftolozane/tazobactam-non-susceptible K. pneumoniae and P. aeruginosa , the majority carried carbapenemases. The most prevalent carbapenemase observed among E. coli (estimated at 0.7% of all isolates), K. pneumoniae (4.8%) and P. aeruginosa (10.0%) was an MBL. Almost all imipenem/relebactam-non-susceptible E. coli and K. pneumoniae carried MBL or OXA-48-like carbapenemases, whereas among imipenem/relebactam-non-susceptible P. aeruginosa , 56% carried MBL or GES carbapenemases. Conclusions: Ceftolozane/tazobactam and imipenem/relebactam may provide treatment options for patients infected with β-lactam-non-susceptible Gram-negative bacilli, excluding isolates carrying an MBL- or OXA-48-like carbapenemase. (© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|